We are live on ! Find out more
AC

Aisling Capital Portfolio holdings

AUM $45.3M
1-Year Est. Return 15.24%
This Fund
S&P 500
This Quarter Est. Return
+2.82%
1 Year Est. Return
-15.24%
3 Year Est. Return
+386.13%
5 Year Est. Return
+981.36%
10 Year Est. Return
–
AUM
$463M
AUM Growth
-$299M
Cap. Flow
-$321M
Cap. Flow %
-69.31%
Top 10 Hldgs %
100%
Holding
9
New
–
Increased
–
Reduced
4
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$235M
2
VRAY
ViewRay, Inc.
VRAY
+$56.5M
3
ASXC
Asensus Surgical, Inc.
ASXC
+$20.8M
4
AIMT
Aimmune Therapeutics
AIMT
+$7.07M

Sector Composition

Rank Sector Weight
1 Healthcare 99.76%
2 Miscellaneous 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
$348M 75.27%
2,038,920
-1,400,000
-41% -$235M
AIMT
2
DELISTED
Aimmune Therapeutics
AIMT
$54.3M 11.73%
1,990,000
-250,000
-11% -$7.07M
ADMA icon
3
ADMA Biologics
ADMA
$2.09B
$22.4M 4.84%
3,608,171
– –
VRAY
4
DELISTED
ViewRay, Inc.
VRAY
$16.2M 3.51%
1,735,988
-5,744,899
-77% -$56.5M
ASXC
5
DELISTED
Asensus Surgical, Inc.
ASXC
$13.9M 2.99%
183,796
-307,693
-63% -$20.8M
CDTX
6
DELISTED
Cidara Therapeutics
CDTX
$4.49M 0.97%
51,057
– –
CMRX
7
DELISTED
Chimerix, Inc.
CMRX
$1.84M 0.4%
472,943
– –
PTX
8
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$202K 0.04%
210,000
– –

Similar funds

SCPM
Sagard Capital Partners Management New York $46.7M AUM 23.43% 1-Year Est. Return
ZIM
ZPR Investment Management Orange City, Florida $46.8M AUM 2.45% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return
INL
IPC/NYCG LLC New York $43.3M AUM 61.41% 1-Year Est. Return
CP
Clover Partners Dallas, Texas $43.1M AUM 4.09% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
JCM
Julex Capital Management Wellesley, Massachusetts $42.4M AUM 9.78% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return

Aisling Capital's Q3 2018 Portfolio in Review

As of Q3 2018, Aisling Capital held 9 positions worth $463M, down 39% from $762M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Aisling Capital withdrew a net $321M in Q3 2018, reducing 4 holdings. Its largest reduction was Loxo Oncology, Inc, cutting an estimated $235M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

  • Aisling Capital's biggest Q3 2018 reduction was Loxo Oncology, Inc, cutting an estimated $235M.
  • Aisling Capital's ten largest holdings make up 100% of its $463M portfolio in Q3 2018.
  • Aisling Capital opened 0 new positions and closed 0 in Q3 2018.
  • Aisling Capital's portfolio value fell 39% quarter-over-quarter to $463M.

Based on Aisling Capital's 13F filing for Q3 2018, filed 5 Nov 2018.